Fibrosis regression induced by intravenous gammaglobulin treatment
(2003) In Annals of the Rheumatic Diseases 62(2). p.175-177- Abstract
- Objectives: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. Methods: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjogren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. Results: Fibrotic excess... (More)
- Objectives: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. Methods: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjogren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. Results: Fibrotic excess was reduced in all the patients by IVIg treatment. In five patients the disease as a whole benefited from the infusion of immunoglobulins. Conclusion: IVIg may enhance resorption of fibrosis and promote healing in patients with fibrotic associated disorders. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/891347
- author
- Amital, H ; Rewald, E ; Levy, Y ; Bar-Dayan, Y ; Manthorpe, Rolf LU ; Engervall, P ; Sherer, Y ; Langevitz, P and Shoenfeld, Y
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of the Rheumatic Diseases
- volume
- 62
- issue
- 2
- pages
- 175 - 177
- publisher
- BMJ Publishing Group
- external identifiers
-
- pmid:12525390
- wos:000180577000015
- scopus:0344341646
- ISSN
- 1468-2060
- DOI
- 10.1136/ard.62.2.175
- language
- English
- LU publication?
- yes
- id
- 20c8710c-2dcc-4003-9a84-5f7bc058f3af (old id 891347)
- date added to LUP
- 2016-04-01 16:18:07
- date last changed
- 2022-01-28 18:44:52
@article{20c8710c-2dcc-4003-9a84-5f7bc058f3af, abstract = {{Objectives: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. Methods: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjogren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. Results: Fibrotic excess was reduced in all the patients by IVIg treatment. In five patients the disease as a whole benefited from the infusion of immunoglobulins. Conclusion: IVIg may enhance resorption of fibrosis and promote healing in patients with fibrotic associated disorders.}}, author = {{Amital, H and Rewald, E and Levy, Y and Bar-Dayan, Y and Manthorpe, Rolf and Engervall, P and Sherer, Y and Langevitz, P and Shoenfeld, Y}}, issn = {{1468-2060}}, language = {{eng}}, number = {{2}}, pages = {{175--177}}, publisher = {{BMJ Publishing Group}}, series = {{Annals of the Rheumatic Diseases}}, title = {{Fibrosis regression induced by intravenous gammaglobulin treatment}}, url = {{http://dx.doi.org/10.1136/ard.62.2.175}}, doi = {{10.1136/ard.62.2.175}}, volume = {{62}}, year = {{2003}}, }